Back to top









MTN-020, or ASPIRE (A Study to Prevent Infection with a Ring for Extended Use), was a Phase III study to determine whether a vaginal ring containing the ARV drug dapivirine is a safe and effective method for protecting against the sexual transmission of HIV when used by women for a month at a time. ASPIRE enrolled 2,629 sexually active HIV-negative women ages 18-45 and was conducted between 2012-2015 at 15 clinical research sites in Malawi, South Africa, Uganda and Zimbabwe. Results, reported in 2016, found HIV risk was reduced by 27 percent overall and no safety concerns.  HIV risk was cut by more than half (56 percent) in women older than 21, who also appeared to use the ring most consistently.  Results of an exploratory analysis reported at AIDS 2016 found the level of HIV protection for those who used the ring most consistently was at least 56 percent and as high as 75 percent or more with near perfect use.



Sensitive ARV resistance tests detect no dapivirine-associated resistance among women using dapivirine vaginal ring in ASPIRE



Researchers present additional evidence on the safety of the dapivirine vaginal ring for HIV prevention in women



Women facing intimate partner violence were less likely to use vaginal ring in ASPIRE



Dapivirine ring did not confer drug resistance among women who acquired HIV in ASPIRE



HOPE open-label study of vaginal ring for preventing HIV begins for former ASPIRE participants



Used consistently, monthly vaginal ring may be highly effective against HIV in women, suggest new analyses from ASPIRE



Dapivirine vaginal ring helped protect women against HIV in ASPIRE Phase III trial



ASPIRE Results At-A-Glance



ASPIRE Q&A on Results



See Also

Two Large Studies Show IPM’s Monthly Vaginal Ring Helps Protect Women Against HIV



Sister Studies: The Ring Study and ASPIRE



Other Study Milestones

Researchers complete ASPIRE Phase III trial of the dapivirine vaginal ring for HIV prevention in women; results are expected early 2016



ASPIRE Phase III trial of a vaginal ring for HIV prevention completes enrollment of 2,629 women



Phase III Trial of Dapivirine Ring Begins in Africa: ASPIRE testing new HIV prevention approach for women



See Also

MTN-020 (ASPIRE) Protocol


MTN-020 (ASPIRE) Study Page